Mersana Therapeutics Inc. (NASDAQ:MRSN) released initial data from the Phase 1 dose escalation and backfill cohorts for ...

Cancer drug developer Mersana Therapeutics (NASDAQ:MRSN) hit a 52-week low on Friday after sharing early clinical results ...

Analyst Charles Zhu from LifeSci Capital maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report) and keeping the price target ...

Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Mersana on Friday said the new designation covers the drug, XMT-1660, for the treatment of advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 low or ...

Mersana Therapeutics Inc (MRSN) stock saw a decline, ending the day at $1.36 which represents a decrease of $-0.03 or -2.16% from the prior close of $1.39. The stock opened at $1.41 and touched a low ...

Citigroup has recently resumed Mersana Therapeutics Inc (MRSN) stock to Buy rating, as announced on November 15, 2024, according to Finviz. Earlier, on March 19, 2024, JP Morgan had raised the stock ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eight ...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ EPS, expectations were $-0.17.

Mersana Therapeutics, Inc. has a twelve month low of $1.22 and a twelve month high of $6.28. The company’s 50-day moving average price is $2.17 and its 200-day moving average price is $1.97.

Shares of Mersana Therapeutics jumped Wednesday after the company's loss narrowed and its third-quarter results topped analysts' expectations. The stock was up 23% to $2.71 in morning trading.